Quick Listen: Scrip's Five Must-Know Things

Jun 17 2024

In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks.

Scrip Five Must Know Things — weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 June 2024, including: Boehringer Ingelheim GmbH best in MASH?; biopharma funding on an upswing?; Moderna, Inc.’s combo jab; clinical trial recover from pandemic; and Astellas Pharma, Inc.’s US commercial head speaks.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data" - Scrip, 7 June, 2024.)

(Also see "Financial Market At The Start Of An Upswing, For Companies With Focused Strategies" - Scrip, 13 June, 2024.)

(Also see "Moderna Pips Pfizer/BioNTech In Combo Jab Race" - Scrip, 10 June, 2024.)

(Also see "What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet" - Scrip, 12 June, 2024.)

(Also see "Astellas’s US Commercial Head Petroutsas On New Launches" - Scrip, 11 June, 2024.)

Citeline · Scrip's Five Must-Know Things - 17 June 2024

Open Media

Finance Watch: Lila Sciences Raises $235m To Refine Its AI Factories For Drugs And More

Sep 18 2025

• By Mandy Jackson

Private Company Edition: Flagship’s Lila secures big series A cash six months after $200m seed funding announced in March. Also, Reunion Neuroscience increases its series A to $133m, Dualitas launches with $65m and Tasca grows its series A to $67m as its lead drug enters Phase I/II.

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

Sep 17 2025

• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

GSK Unveils Multi-Billion US Investment As Trump Visits UK

Sep 17 2025

• By Andrew McConaghie

The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.

Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US

Sep 15 2025

• By Mandy Jackson

Public Company Edition: The neuropsychiatric disease-focused firm grossed $285m in the first IPO in the US above $100m since February. Also, Avidity raised $600m in a follow-on offering, Alnylam priced a $575m note sale and Propanc joins MEI in biopharma’s cryptocurrency ranks.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

Sep 22 2025

• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.